High-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. From total to focal ablation
https://doi.org/10.17650/1726-9776-2020-16-3-153-164
Abstract
A review of the literature is devoted to the urgent issue of modern oncourology — the treatment of prostate cancer using high-intensity focused ultrasound (HIFU). Currently, there is a trend in shifting the approach from total to focal ablation in patients with prostate cancer of low risk in order to reduce the profile of complications. The article presents the results of modern research on HIFU in both total and focal ablation. Data on oncological, functional results of treatment are given.
About the Authors
I. A. Aboyan
Clinical and Diagnostic Center “Zdorovie”
Russian Federation
Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.
Competing Interests: The authors declare no conflict of interest.
S. M. Pakus
Clinical and Diagnostic Center “Zdorovie”
Russian Federation
Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.
Competing Interests: The authors declare no conflict of interest.
K. I. Badyan
Clinical and Diagnostic Center “Zdorovie”
Russian Federation
Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.
Competing Interests: The authors declare no conflict of interest.
A. V. Hasigov
Department of Radiation Diagnostics with Radiation Therapy and Oncology, North Osetian State Medical Academy, Ministry of Health of Russia
Russian Federation
Competing Interests: The authors declare no conflict of interest.
Russian Federation
40 Pushkinskaya St., Vladikavkaz 362019, Republic of North Ossetia.
Competing Interests: The authors declare no conflict of interest.
A. M. Galstyan
Clinical and Diagnostic Center “Zdorovie”
Russian Federation
Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.
Competing Interests: The authors declare no conflict of interest.
References
1. Alekseev B.Ya., Kaprin A.D., Kolontarev K.B. et al. Prostate cancer. Clinical Recommendations. Russian Society of Urology. Association of Oncologists of Russia. Russian Society of Oncourologists. Russian Society of Clinical Oncology. Moscow, 2018. (In Russ.).
2. Alyaev Yu.G., Glybochko P.V., Pushkar D.Yu. Urology. Russian Clinical Recommendations. Moscow: GEOTARMedia, 2016. 496 p. (In Russ.).
3. Pushkar D.Yu., Govorov A.V., Sidorenkov A.V. et al. Early diagnosis of prostate cancer. Guidelines No. 19. Moscow: ABV-press, 2015. 56 p. (In Russ.).
4. State of oncological care in Russia in 2016. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2017. 236 p. (In Russ.).
5. Rusakov I.G., Gritskevich A.A. Modern views on the treatment of castrationresistant prostate cancer. Prakticheskaya Oncologiya = Practical Oncology 2012;13(3):156-65. (In Russ.).
6. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7-30. DOI: 10.3322/caac.21332.
7. Khmara T.G., Chekhonatskaya M.L., Priezheva V.N. et al. Comparative analysis of clinical, laboratory and radiation diagnostic methods for prostate cancer taking into account the histomorphological gradation of the tumor according to the Gleason score. Byulleten' meditsinskikh internet-konferentsiy = Bulletin of Online Medical Conferences 2014;4(1):68-71. (In Russ.).
8. Apolikhin O.I., Alekseev B.Ya., Sivkov A.V. et al. Complex radiation and pathomorphological diagnosis of prostate cancer. Ul'trazvukovaya i funkcio-nal'naya diagnostika = Ultrasound and Functional diagnostics 2015;4:18. (In Russ.).
9. Pavlova T.V., Bessmertnyy D.V., Pavlov I.A. Prostate cancer as an interdisciplinary problem (review of literature and own research). Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya: Meditsina. Farmatsiya = Scientific Reports of Belgorod State University. Series: Medicine. Pharmacy 2012;20(22-2 (141)):93-6. (In Russ.).
10. Moiseev P.I., Yakimovich G.V., Okeanov A.T. et al. Cancer in Europe: a look at the problem, a comparative analysis of some indicators. Onkologicheskiy zhurnal = Oncology Magazine 2014;8(3):13-23. (In Russ.).
11. Petrov S.B., Rakul S.A., Galimov R.D. Treatment of prostate cancer. Prakticheskaya onkologiya = Practical Oncology 2008;9(2):83. (In Russ.).
12. De Carvalho T.M., Heijnsdiyk E.A., de Koning H.J. Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study. BJU Int 2017;119(4):560-6. DOI: 10.1111/bju.13542.
13. Klotz L. Active surveillance for prostate cancer: a review. Arch Esp Urol 2011;64(8):806-14.
14. Dalela D., Karabon P., Sammon J. et al. Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) results to contemporary North American men with prostate cancer. Eur Urol 2017;71(4):511-4. DOI: 10.1016/j.eururo.2016.08.048.
15. Wilt T.J., Brawer M.K., Jones K.M. et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203-13. DOI: 10.1056/NEJMoa1113162.
16. Lumpov I.S., Amosov A.V., Krupinov G.E. et al. Focal treatment of patients with prostate cancer with focused high-intensity ultrasound (HIFU). Meditsinskiy vestnik Bashkortostana = Medical Bulletin of Bashkortostan 2015;10(3):157-9. (In Russ.).
17. Schulman A.A., Polascik T.J. Most of patients with localized prostate cancer will be treated in the future? Opinion: No. Int Braz Urol 2017;43(4):584-7. DOI: 10.1590/S1677-5538.IBJU.2017.04.03.
18. Stabile A., Dell'Oglio P., De Cobelli F. et al. Association between Prostate Imaging Reporting and Data System (PI-RADS) score for the index lesion and multifocal, clinically significant prostate cancer. Eur Urol Oncol 2018;1(1):29-36. DOI: 10.1016/j.euo.2018.01.002.
19. Van der Poel H.G., van den Bergh R.C.N., Briers E. et al. Focal therapy in primary localised prostate cancer: The European Association of Urology position in 2018. Eur Urol 2018;74(1):84-91. DOI: 10.1016/j.eururo.2018.01.001.
20. Suleymanov E.A., Filonenko E.V., Moskvicheva L.I. et al. The possibilities of HIFU therapy at the present stage. Issledovaniya i praktika v meditsine = Research and Practical Medicine Journal 2016;3(3): 76-82. (In Russ.).
21. Alkhorayef M., Mahmoud M.Z., Alzimami K.S. et al. High-Intensity Focused Ultrasound (HIFU) in localized prostate cancer treatment. Pol J Radiol 2015;80:131-41. DOI: 10.12659/PJR.892341.
22. Aboyan I.A., Galstyan A.M., Grankina A.O., Maksimov A.Yu. HIFU: prospects of application in oncourology. Politematicheskiy setevoy elektronnyy nauchnyy zhurnal Kubanskogo gosudarstvennogo agrarnogo universiteta = Polythematic Network Electronic Scientific Journal of the Kuban State Agrarian University 2016;(122):264-77. (In Russ.).
23. Aboyan I.A., Badyan K.I., Pakus S.M. et al. Place HIFU in the treatment of prostate cancer. The current state of the problem (literature review). Ural'skiy meditsinskiy zhurnal = Ural Medical Journal 2017;(146):69-74. (In Russ.).
24. Warmuth M., Johansson T., Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Mad Eur Urol 2010;58(6):803-15. DOI: 10.1016/j.eururo.2010.09.009.
25. Chaussy Ch., Tilki D., Thuroff S. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: current role. J Cancer Ther 2013;4:59-73.
26. Mc Dannold N., Hynynen K. Quality assurance and system stability of a clinical MRI-guided focused ultrasound system: four-year experience. Med Phys 2006;33(11):4307-13. DOI: 10.1118/1.2352853.
27. Linke C.A., Carstensen E.L., Frizzell L.A. et al. Localized tissue destruction by high-intensity focused ultrasound. Arch Surg 1973;107(6):887-91. DOI: 10.1001/archsurg.1973.01350240053015.
28. Bamber J.C., Hill C.R. Ultrasonic attenuation and propagation speed in mammalian tissues as a function of temperature. Ultrasound Med Biol 1979;5(2):149-57. DOI: 10.1016/0301-5629(79)90083-8.
29. Frizzell L.A. Threshold dosages for damage to mammalian liver by high intensity focused ultrasound. IEEE Trans Ultrason Ferroelectr Freq Control 1988;35(5):578-81. DOI: 10.1109/58.8036.
30. Goss S., Fry F. The effect of high intensity ultrasonic irradiation on tumor growth. IEEE Trans. Sonics Ultrason 1984; SU-31(5):491-6.
31. Ma C.M., Chen X., Cvetkovic D., Chen L. An in-vivo investigation of the therapeutic effect of pulsed focused ultrasound on tumor growth. Med Phys 2014;41(12):122901. DOI: 10.1118/1.4901352.
32. Aboyan I.A., Badyan K.I., Grachev S.V. et al. Prostate cancer: topical staging and prediction issues. Zhurnal fundamental'noy meditsiny i biologii = Journal of Basic Medicine and Biology 2016;(3):51-5. (In Russ.).
33. Marshall S., Taneja S. Focal therapy for prostate cancer: the current status. Prostate Int 2015;3(2):35-41. DOI: 10.1016/j.prnil.2015.03.007.
34. Barnett S.B., ter Haar G.R., Ziskin M.C. et al. Current status of research on biophysical effects of ultrasound. Ultrasound Med Biol 1994;20(3):205-18. DOI: 10.1016/0301-5629(94)90060-4.
35. Curiel L., Chavrier F., Gignoux B. et al. Experimental evaluation of lesion prediction modelling in the presence of cavitation bubbles: intended for high-intensity focused ultrasound prostate treatment. Med Biol Eng Comput 2004;42(1):44-54. DOI: 10.1007/BF02351010.
36. Eggener S.E., Scardino P.T., Carroll P.R. et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Urology 2007;178(6):2260-7. DOI: 10.1016/j.juro.2008.04.045.
37. Aboyan I.A., Galstyan A.M., Badyan K.I., Pakus S.M. HIFU hemiablation in patients with localized forms of prostate cancer. Eksperimental'naya i klinicheskaya urologiya = Experimental and Clinical Urology 2018;(1):42-6. (In Russ.).
38. Madersbacher S., Pedevilla M., Vingers L. et al. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995;55(15):3346-51.
39. Chapelon J.Y., Ribault M., Vernier F. et al. Treatment of localised prostate cancer with transrectal high intensity focused ultrasound. Eur J Ultrasound 1999;9(1):31-8. DOI: 10.1016/s0929-8266(99)00005-1.
40. Chaussy C.G., Thuroff S. High-intensity focused ultrasound for the treatment of prostate cancer: a review. J Endourology 2017;31(S1):S30-7. DOI: 10.1089/end.2016.0548.
41. Crouzet S., Rouviere O., Martin X., Gelet A. High-intensity focused ultrasound as focal therapy of prostate cancer. Curr Opin Urology 2014;24(3):225-30. DOI: 10.1016/s0929-8266(99)00005-1.
42. Chapelon J.Y., Rouviere O., Crouzet S., Gelet A. Prostate Focused Ultrasound Therapy. Adv Exp Med Biol 2016;880:21-41. DOI: 10.1007/978-3-319-22536-4_2.
43. Ganzer R., Franiel T., Kollermann J. et al. Focal therapy of prostate cancer. Urology A 2017;56(10):1335-46. DOI: 10.1007/s00120-017-0488-z.
44. Sundaram K.M., Chang S.S., Penson D.F., Arora S. Therapeutic ultrasound and prostate cancer. Semin Int Radiol 2017;34(2):187-200. DOI: 10.1055/s-0037-1602710.
45. Veereman G., Jonckheer P., Desomer A. et al. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for localised prostate cancer. Eur Urol Focus 2015;1(2):158-70. DOI: 10.1016/j.euf.2015.04.006.
46. Solovov V.A., Orlov A.E., Vozdvizhenskiy M.O. et al. High-intensity focused ultrasound ablation (HIFU) of prostate cancer in 976 patients: 7-year results. Izvestiya Samarskogo nauchnogo tsentra RAN = Bulletin of the Samara Scientific Center of the Russian Academy of Sciences 2015;17(2-3):682-5. (In Russ.).
47. Gubanov E.S., Boryaev E.A., Zimichev A.A. Urological complications of HIFU-therapy of prostate cancer: international and domestic experience. Samarskiy gosudarstvennyy meditsinskiy universitet = Samara State Medical University 2016;(1-2):133-8. (In Russ.).
48. Alyaev Yu.G., Krupinov G.E., Grigoryan V.A. et al. High-intensity focused ultrasound in the treatment of prostate cancer. Onkourologiya = Cancer Urology 2007;(2):34-41. (In Russ.).
49. Glybochko P.V., Fomkin R.N., Ponukalin A.N. et al. First experience with high intensity focused ultrasound ablation (HIFU) in the treatment of prostate cancer. Saratovskiy nauchno-medicinskii zhurnal = Saratov Journal of Medical Scientific Research 2009;5(4):599-603. (In Russ.).
50. Dickinson L., Arya M., Afzal N. et al. Medium-term outcomes after whole-gland high-intensity focused ultrasound for the treatment of nonmetastatic prostate cancer from a multicentre registry cohort. Eur Urol 2016;70(4):668-74. DOI: 10.1016/j.eururo.2016.02.054.
51. Ramsay C.R., Adewuyi T.E., Gray J. et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2015;19(49):1-490. DOI: 10.3310/hta19490.
52. Pfeiffer D., Berger J., Gross A. Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: treatment-related predictors of biochemical outcomes. Asian J Urology 2015;2(1):46-52. DOI: 10.1016/j.ajur.2014.08.009.
53. Chen P.Y., Chiang P.H., Liu Y.Y. et al. Primary whole gland ablation for localized prostate cancer with high-intensity focused ultrasound: the important predictors of biochemical recurrence. Int J Urology 2018;25(6):615-20. DOI: 10.1111/iju.13581.
54. Krupinov G.E. Treatment of patients with prostate cancer with high-intensity focused ultrasound. Dis. ... doctor of medical sciences: 14.01.23. Moscow, 2010. 246 p. (In Russ.).
55. Badyan K.I. Modern approaches to predicting the risk of recurrence of prostate cancer after HIFU. Abstract of thesis of the candidate of medical sciences, 2018. (In Russ.).
56. Imankulov S.B., Zhampeyisov N.K., Oskenbaeva K.K. Ultrasound ablation (HIFU therapy) in the treatment of kidney cancer. Klinicheskaya meditsina Kazahstana = Clinical Medicine of Kazakhstan 2014;1(31):91-2. (In Russ.).
57. Fomkin R.N., Shatylko T.V. Nadir PSA as the main predictor of relapse of localized prostate cancer after HIFU ablation. Urology 2016;(5):489-96. (In Russ.).
58. Guliyev F.A. Predictors of biochemical progression of prostate cancer. Kazanskiy medicinskiy zhurnal = Kazan Medical 2017;98(6):890-4. (In Russ.).
59. Ganzer R., Fritsche H.M., Brandtner A. et al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int 2013;112(3):322-9. DOI: 10.1111/j.1464-410X.2012.11715.x.
60. Neymark A.I., Tachalov M.A., Neymark B.A. Features of HIFU (high intensity focfused ultrasound)-therapy in the treatment of localized prostate cancer. Meditsina i obrazovanie v Sibiri = Journal of Siberian Medical Sciences 2013;(5):17. (In Russ.).
61. Popkov V.M., Fomkin R.N., Blumberg B.I. Prognostic factors in evaluating the effectiveness of treatment results for patients with localized prostate cancer using HIFU ablation. Saratovskiy nauchno-meditsinskiy zhurnal = Saratov Journal of Medical Scientific Research 2013;9(1):116-21. (In Russ.).
62. Edison E., Tariq Shah T., Ahmed H.U. Focal ablation of early-stage prostate cancer: candidate selection, treatment guidance, and assessment of outcome. Urol Clin North Am 2017;44(4):575-85. DOI: 10.1016/j.ucl.2017.07.006.
63. Bostwick D.G., Waters D.J., Farley E.R. et al. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007;70(6 Suppl):42-4. DOI: 10.1016/j.urology.2007.07.037.
64. De la Rosette J., Ahmed H., Barentsz J. et al. Focal therapy in prostate cancerreport from a consensus panel. J Endourol 2010;24(5):775-80. DOI: 10.1089/end.2009.0596.
65. Ahmed H.U., Akin O., Coleman J.A. et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2012;109(11):1636-47. DOI: 10.1111/j.1464-410X.2011.10633.x.
66. Langley S., Ahmed H.U., Al-Qaisieh B. et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 2012;109 (Suppl 1):7-16. DOI: 10.1111/j.1464-410X.2011.10825.x.
67. Donaldson I.A., Alonzi R., Barratt D. et al. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol 2015;67(4):771-7. DOI: 10.1016/j.eururo.2014.09.018.
68. Tay K.J., Schulman A.A., Sze C. et al. New advances in focal therapy for early stage prostate cancer. Expert Rev Anticancer Ther 2017;17(8):737-43. DOI: 10.1080/14737140.2017.1345630.
69. Polascik T.J., Mayes J.M., Schroeck F.R. et al. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer 2009;115(10):2104-10. DOI: 10.1002/cncr.24258.
70. Tsivian M., Moreira D.M., Sun L. et al. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urol Oncol 2012;30(1):21-5. DOI: 10.1016/j.urolonc.2009.11.001.
71. Mayes J.M., Mouraviev V., Sun L. et al. Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol 2011;29(2):166-70. DOI: 10.1016/j.urolonc.2009.03.011.
72. Gallina A., Maccagnano C., Suardi N. et al. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. BJU Int 2012;110(2 Pt 2):E64-8. DOI: 10.1111/j.1464-410X.2011.10762.x.
73. Katz B., Srougi M., Camara-Lopes L.H. et al. The accuracy of pathological data for the prediction of insignificant prostate cancer. Int. Braz J Urol 2012;38(6):760-8. DOI: 10.1590/1677-553820133806760.
74. Sinnott M., Falzarano S.M., Hernandez A.V. et al. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy. Prostate 2012;72(11):1179-86. DOI: 10.1002/pros.22467.
75. Washington S.L., Bonham M., Whitson J.M. et al. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. BJU Int 2012;110(1):50-5. DOI: 0.1111/j.1464-410X.2011.10704.x.
76. Berg K.D., Toft B.G., R0der MA et al. Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies? APMIS 2013;121(4):257-65. DOI: 10.1111/j.1600-0463.2012.02965.x.
77. Onik G., Miessau M., Bostwick D.G. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009;27(26):4321-6. DOI: 10.1200/JCO.2008.20.3497.
78. Ahmed H.U., Hu Y., Carter T. et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011;186(2):458-64. DOI: 10.1016/j.juro.2011.03.147.
79. Barqawi A.B., Rove K.O., Gholizadeh S. et al. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol 2011;186(1):80-5. DOI: 10.1016/j.juro.2011.03.005.
80. Hossack T., Patel M.I., Huo A. et al. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. J Urol 2012;188(3):781-5. DOI: 10.1016/j.juro.2012.05.006.
81. Huo A.S., Hossack T., Symons J.L. et al. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. J Urol 2012;187(6):2044-9. DOI: 10.1016/j.juro.2012.01.066.
82. Hu Y., Ahmed H.U., Carter T. et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int 2012;110(6):812-20. DOI: 10.1111/j.1464-410X.2012.10933.x.
83. Long J.A., Hungr N., Baumann M. et al. Development of a novel robot for transperineal needle-based interventions: focal therapy, brachytherapy and prostate biopsies. J Urol 2012;188(4):1369-74. DOI: 10.1016/j.juro.2012.06.003.
84. Crawford E.D., Rove K.O., Barqawi A.B. et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate 2013;73(7):778-87. DOI: 10.1002/pros.22622.
85. Losa A., Gadda G.M., Lazzeri M. et al. Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy. Urology 2013;81(6):1291-6. DOI: 10.1016/j.urology.2012.11.078.
86. Glybochko P.V., Voskanyan G.A., Vinarov A.Z. et al. Visualization of prostate cancer using magnetic resonance spectroscopy. Meditsinskiy vestnik Bashkortostana = Medical Bulletin of Bashkortostan 2013;8(2):241-5. (In Russ.).
87. Sadchenko A.V., Govorov A.V., Pushkar D.Yu., Vasiliev A.O. Saturation biopsy of the prostate gland (literature review). Onkourologiya = Cancer Urology 2013;9(3):70-5. (In Russ.).
88. Korobkin A.S., Sharia M.A., Voskanyan G.A., Vinarov A.Z. Multiparameter magnetic resonance imaging in the diagnosis of prostate cancer. Andrology and Genital Surgery 2015;16(1):53-61. (In Russ.).
89. Muto S., Yoshii T., Saito K. et al. Focal therapy with high-intensity-focused ultrasound in the treatment localized prostate cancer. Jpn J Clin Oncol 2008;38(3):192-9. DOI: 10.1093/jjco/hym173.
90. Van Velthoven R., Aoun F., Marcelis Q. et al. A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2016;19(1):79-83. DOI: 10.1038/pcan.2015.55.
91. Albisinni S., Aoun F., Bellucci S. et al. Comparing high intensity focal ultrasound hemiablation to robotic radical prostatectomy in the management of unilateral prostate cancer: a matched-pair analysis. J Endourology 2017;31(1):14-9. DOI: 10.1089/end.2016.0702.
92. Fegoun A.B., Barret E., Prapotnich D. et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol 2011;37(2):213-9; discussion 220-2. DOI: 10.1590/s1677-55382011000200008.
93. Ahmed H.U., Freeman A., Kirkham A. et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011;185(4):1246-54. DOI: 10.1016/j.juro.2010.11.079.
94. Coleman J.A. Functional outcomes of partial prostate ablation and focal therapy: are we managing expectations of a bar set too high. Curr Opin Urology 2015;25(3):220-4. DOI: 10.1097/MOU.0000000000000169.
95. Ahmed H.U., Dickinson L., Charman S. et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol 2015;68(6):927-36. DOI: 10.1016/j.eururo.2015.01.030.
96. Feijoo E.R., Sivaraman A., Barret E. et al. Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes. Eur Urol 2016;69(2):214-20. DOI: 10.1016/j.eururo.2015.06.018.
97. Ganzer R., Hadaschik B., Pahernik S. et al. Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound. J Urol 2018;199(4):983-9. DOI: 10.1016/j.juro.2017.10.033.
98. Rischmann P., Gelet A., Riche B. et al. Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol 2017;71(2):267-73. DOI: 10.1016/j.eururo.2016.09.039.
99. Albisinni S., Melot C., Aoun F. et al. Focal treatment for unilateral prostate cancer using HIFU: a comprehensive study of pooled data. J Endourol 2018;32(9):797-804. DOI: 10.1089/end.2018.0130.
100. Walker Faure N.A., Norris J.M., Shah T.T. et al. A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: a systematic review. Urol Oncol 2018;36(2):67-7. DOI: 10.1016/j.urolonc.2017.12.002.
101. Golan R., Bernstein A.N., McClure T.D. et al. Partial gland treatment of prostate cancer using high-intensity focused ultrasound in the primary and salvage settings: a systematic review. J Urol 2017;198(5):1000-9. DOI: 10.1016/j.juro.2017.03.137.
102. Guillaumier S., Peters M., Arya M. et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol 2018;74(4): 422-9. DOI: 10.1016/j.eururo.2018.06.006.
103. Stabile A., Orczyk C., Hosking-Jervis F. et al. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int 2019;124(3):431-40. DOI: 10.1111/bju.14710.
104. Lebastchi A.H., George A.K., Polascik T.J. et al. Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus. Eur Urol 2020. DOI: 10.1016/j.eururo.2020.05.018.
Review
For citations:
Aboyan I.A., Pakus S.M., Badyan K.I., Hasigov A.V., Galstyan A.M. High-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. From total to focal ablation. Cancer Urology. 2020;16(3):153-164. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-3-153-164
Views:
1072
Email this article 